KidneyPort

Wearable Artificial Kidney

KidneyPort aims at the widening of the two persistent technical bottlenecks of hemodialysis. The first is the still-limited blood-compatibility of dialysis membranes, i.e. the propensity of membrane biomaterials to activate clotting in contacting blood resulting in adherent or embolic thrombi. The second bottleneck is the confined capacity of current dialysis membranes to remove protein-bound toxins from the patient’s blood. KidneyPort strives to achieve these goals through the use of a new hydrophilic biomaterial “SlipSkin™”. It is produced by one of the partners of this consortium (INterface BIOmaterials BV), and the biomaterial has already been studied extensively. The consortium will, therefore, take a pragmatic approach, with a focus on prototypes and their testing under realistic conditions. Our drive is that the SlipSkin™ was found to be extremely suitable for use in blood-contacting medical devices, including prototypic dialysis membranes. Moreover, it is known that SlipSkin™ can be blended with nano- or microparticles (e.g., of heparin, silver or active carbon) to produce bio-active surface coatings combining a high affinity for blood-borne toxins and non-thrombogenicity. The consortium’s R&D work will go into two directions:

1) Construction and evaluation of new dialysis membranes which combine the mixed-matrix principle for efficient removal of toxins and an extremely high level of blood-compatibility;

2) Design, construction and evaluation of new purification cassette, which is to be placed in the blood circuit behind the dialysis unit, to specifically remove protein-bound toxins via engineered adsorption.

The KidneyPort consortium consists of three research centres; (i) University of Twente – MIRA Institute of Biomedical Technology – Biomaterials Science & Technology Department (Enschede), (ii) Maastricht University – Biomedical Engineering FMHL (Maastricht) and (iii) Maastricht University Medical Centre – Internal Medicine/Nephrology (Maastricht) and four companies; (i) INterface BIOmaterials BV (Chemelot Campus, Geleen), (ii) Interdos Pharma BV (Chemelot Campus, Geleen); (iii) Labo Group BV (Tilburg) and (iv) LifeTec Group BV (Eindhoven).

The project is subsidised by the Dutch Kidney Foundation and Topsector Life Science and Health for a 4 year period (2014-2018).

  • Latest news:

    February 2015:

    PMLF laboratory technology/biotechnology accreditation

     

    February 2014:

    INterface BIOmaterials BV participates in the LSH impuls project: “KidneyPort

     

    August 2013:

    PMLF laboratory technology accreditation

     

    July 2013:

    PMLF process engineering accreditation

     

    February 2013:

    CE certification on X-Spheres™

     

    November 2012:

    ISO 13485 certification

     

    January 2011:

    INterface BIOmaterials BV participates in the Interreg IVa project: “BioMiMedics”

     

    January 2010:

    INterface BIOmaterials BV participates in the “iNephron” project subsidized by the Dutch Kidney Foundation